WCMNY
HZNP

Westchester Capital Management (New York)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Westchester Capital Management (New York)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,026,094
Closed -$234M – 358
2023
Q3 		$234M Sell
2,026,094
-231,370
-10% -$24.9M 6.84% 2
2023
Q2 		$232M Buy
2,257,464
+214,462
+10% +$22.6M 7.3% 1
2023
Q1 		$223M Buy
2,043,002
+789,958
+63% +$87.3M 6.76% 1
2022
Q4 		$143M Buy
+1,253,044
New +$104M 3.92% 2

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Westchester Capital Management (New York)'s HZNP Position: Q4 2023 in Review

Westchester Capital Management (New York) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,026,094 shares — an estimated $234M sold.

Westchester Capital Management (New York) first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $234M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Westchester Capital Management (New York) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 2,026,094 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $234M.
  • Westchester Capital Management (New York) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Westchester Capital Management (New York)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $234M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Westchester Capital Management (New York)'s 13F filing for Q4 2023, filed 15 Feb 2024.